FDA, inaprubahan ang apat na COVID-19 test kits

By Angellic Jordan March 19, 2020 - 04:00 PM

Nasa apat na COVID-19 test kits ang inaprubahan ng Food and Drug Administration (FDA).

Inilabas ng FDA ang inisyal na listahan ng mga aprubadong COVID-19 test kits para sa commercial use.

Kabilang dito ang mga sumusunod:
– Nucleic acid detection kit for 2019 ncov
(Manufacturer: Shanghai GenoeDx Biotech Co., LTD-Shanghai, China)
(Distributor: S&S Enterprises)

– Novel coronavirus 2019-ncov nucleic and detection kit (fluorescence PCR method)
(Manufacturer: Beijing Applied Biological Technologies Co., Ltd-Changing District 102206 Beijing P.R.
(Distribution: Sahar Internation)

– AllplexTM 2019-nCoV Assay
(Manufacturer: Seegene Inc. Seoul, Republic of Korea)
(Distributor: Endure Medical, Inc.)

– SOLGENT DiaPlexQ Novel Coronavirus (2019-nCoV) Detection Kit
(Manufacturer: Solgent Co., Ltd-3F, 32, Techno 6-ro, Yuseong-gu, Daejeon, South Korea)
(Distributor: Wellness Pro Incorporated)

Sinabi ng ahensya na ang mga nasabing kit ay nakapag-comply sa itinakdang requirements batay sa FDA memorandum no. 2020-006 o “Issuance of Special Certification for Imported Test Kits of COVID-19.”

Paalala ng FDA, ireport ang pagbebenta ng mga COVID-19 test kit na hindi kabilang sa listahan sa kanilang online reporting facility na eReport sa www.fda.gov.ph/report o e-mail sa [email protected].

TAGS: COVID-19 test kits, FDA, Novel coronavirus 2019-ncov nucleic and detection kit (flourescence PCR method), Nucleic acid detection kit for 2019 ncov, SOLGENT DiaPlexQ Novel Coronavirus (2019-nCoV) Detection Kit, COVID-19 test kits, FDA, Novel coronavirus 2019-ncov nucleic and detection kit (flourescence PCR method), Nucleic acid detection kit for 2019 ncov, SOLGENT DiaPlexQ Novel Coronavirus (2019-nCoV) Detection Kit

Disclaimer: The comments uploaded on this site do not necessarily represent or reflect the views of management and owner of Cebudailynews. We reserve the right to exclude comments that we deem to be inconsistent with our editorial standards.

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.